Adrián Llerena
CICAB
Clinical Research Centre
Extremadura University Hospital & Medical School
Badajoz 06080
Spain
Name/email consistency: high
- Relevance of CYP2D6 for risperidone pharmacokinetics, pharmacodynamics and adverse reactions. Llerena, A., Dorado, P., Peñas-Lledó, E.M. Pharmacogenomics (2011)
- Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity. Llerena, A., Dorado, P., Peñas-Lledó, E.M. Pharmacogenomics (2009)
- Low frequency of CYP2D6 poor metabolizers among schizophrenia patients. Llerena, A., Dorado, P., Peñas-Lledó, E.M., Cáceres, M.C., De la Rubia, A. Pharmacogenomics J. (2007)
- Hot topic: pharmacogenetic and pharmacogenomics. Llerena, A., Licinio, J. Curr. Drug. Targets (2006)
- Effect of CYP2D6 and CYP2C9 genotypes on fluoxetine and norfluoxetine plasma concentrations during steady-state conditions. LLerena, A., Dorado, P., Berecz, R., González, A.P., Peñas-LLedó, E.M. Eur. J. Clin. Pharmacol. (2004)
- Relationship between haloperidol plasma concentration, debrisoquine metabolic ratio, CYP2D6 and CYP2C9 genotypes in psychiatric patients. LLerena, A., de la Rubia, A., Berecz, R., Dorado, P. Pharmacopsychiatry (2004)
- QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations. Llerena, A., Berecz, R., Dorado, P., de la Rubia, A. J. Psychopharmacol. (Oxford) (2004)
- Determination of fluoxetine and norfluoxetine in human plasma by high-performance liquid chromatography with ultraviolet detection in psychiatric patients. LLerena, A., Dorado, P., Berecz, R., González, A., Jesús Norberto, M., de la Rubia, A., Cáceres, M. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2003)
- Determination of risperidone and 9-hydroxyrisperidone in human plasma by liquid chromatography: application to the evaluation of CYP2D6 drug interactions. LLerena, A., Berecz, R., Dorado, P., de la Garza, C.S., Norberto, M.J., Cáceres, M., Gutiérrez, J.R. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. (2003)
- CYP2C9 gene and susceptibility to major depressive disorder. LLerena, A., Berecz, R., Dorado, P., González, A.P., Peñas-LLedó, E.M., De La Rubia, A. Pharmacogenomics J. (2003)
- QTc interval lengthening is related to CYP2D6 hydroxylation capacity and plasma concentration of thioridazine in patients. LLerena, A., Berecz, R., de la Rubia, A., Dorado, P. J. Psychopharmacol. (Oxford) (2002)
- Determination of clozapine and its N-desmethyl metabolite by high-performance liquid chromatography with ultraviolet detection. Llerena, A., Berecz, R., Norberto, M.J., de la Rubia, A. J. Chromatogr. B Biomed. Sci. Appl. (2001)
- Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes. LLerena, A., Berecz, R., de la Rubia, A., Fernández-Salguero, P., Dorado, P. Ther. Drug. Monit (2001)